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The purpose of this study is to characterize the inflammatory cytokines that are expressed in
peripheral blood mononuclear cells (PBMCs) and THP-1 monocytes exposed to Invisalign®
aligner material in vitro. Invisalign® material was ground into particles, soaked in artificial saliva,
and the eluate was collected. Commercially available cryopreserved pooled and individual human
PBMCs and THP-1 monocytes were cultured with Invisalign® material eluate and positive
(lipopolysaccharide) and negative controls. The supernatants were collected and used with a
BioLegend LEGENDplex™ multi-analyte flow assay, a sandwich enzyme-linked immunosorbent
assay (ELISA), to identify the expression of TNF-α, IL-6, IL-8, IL-10, IFN-γ, IL-1β, and IL12p70. The results of this study show that Invisalign® material stimulates IL-8 expression in
certain individual donor PBMCs and in THP-1 monocytes. Invisalign® material also stimulates
low levels of TNF-α expression in pooled PBMCs, certain individual donor PBMCs and THP-1
cells. IL-6 was slightly increased in certain individual donor PBMCs. IL-1β was also slightly
stimulated by Invisalign® material in THP-1 cells. IL-10, IL-12p70, IFN-γ, and IL-6 were not
detected after stimulation with Invisalign® material in THP-1 monocytes. Invisalign ® material
stimulated IL-8 expression across experiments, though not significantly, in individual donor
PBMCs and THP-1 monocytes when profiled with a BioLegend LEGENDplex™ multi-analyte
flow assay. IL-8 is a chemokine responsible for directing neutrophils to the site of inflammation.
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CHAPTER 1: INTRODUCTION
Invisalign® is clear aligner system used in orthodontic treatment to treat malocclusions. It
is used worldwide and over 9 million patients have been treated with this product (Invisalign®
2020). The clear trays are a more esthetic option than traditional fixed appliances and have drawn
more patients, especially adults, into orthodontic treatment (Kravitz et al. 2009).
The side effects of treatment with Invisalign® may include pain, difficulty with speech
and chewing, and mucosal irritations. Many of these side effects decrease with continued wear
and acclimation to the appliance. In 2017, Allareddy et al. found other, potentially more serious,
side effects associated with Invisalign® material when reviewing the Manufacturer and User
Facility Device Experience (MAUDE) database. From 2006-2016 there were 173 reports of side
effects after Invisalign® aligner wear, including difficulty of breathing, hives, anaphylaxis, and
swelling of the gums and tongue, among others (Allareddy et al. 2017). One case report described
a patient who had hives, swelling, and burning of the lips after using Invisalign® material. When
the patient was patch tested with Invisalign® material, they were deemed to have contact
hypersensitivity (Awosika et al. 2017). Another patient of the University of Nebraska Medical
Center College of Dentistry was diagnosed with swollen gingiva after using Invisalign®, with
biopsy exhibiting foreign body granulomatous inflammation (Narayana N, personal
communication, May 1, 2020).
A previous study on the biologic effect of Invisalign® material showed no cytotoxic
effect (Eliades et al. 2009), whereas another found a slight cytotoxic effect (Martina et al. 2019).
Invisalign® material does not induce estrogenic effects (Eliades et al. 2009) and does not contain
Bisphenol A (BPA) (Kotyk and Wiltshire 2013). Premaraj et al. (2014) found that when
particulate Invisalign® material was added to oral keratinocytes, there was an increase in cell
death and compromised cell membrane integrity. They postulated that this compromised cell
membrane integrity could be from leaching of the material’s components.
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According to the Material Safety Data Sheet, Invisalign® material is a thermoplastic
polyurethane (Material safety data sheet 2015). Although the exact composition is propriety,
diisocyanate is one component that could be responsible for some patients' adverse reactions
(Premaraj et al. 2014). Isocyanates are known to cause asthma and allergic contact dermatitis
(Frick et al. 2003).
Even though immune responses are thought to be the cause of adverse reactions
associated with Invisalign® material, mechanisms of the immune reaction-induced inflammation
have yet to be studied in detail. Peripheral blood mononuclear cells (PBMCs) and THP-1
monocytes are frequently used in studying inflammation and immune response. PBMCs include
lymphocytes (T cells, B cells, and natural killer (NK) cells), monocytes, and dendritic cells
(Kleiveland 2015). THP-1 is an immortalized monocyte cell line derived from the peripheral
blood of a patient with acute monocytic leukemia (Tsuchiya et al. 1980).
The hypothesis of this study is that immunological cytokines expressed by PBMCs and
monocytes after exposure to Invisalign® material drive inflammation. Though there are hundreds
of cytokines, this study was limited to the following cytokines: IL-1β, TNF-α, IL-6, IL-8, IL-12,
IFN-γ, and IL-10. These cytokines are a mix of pro- and anti-inflammatory agents that are
produced by several different immune cell types.
Hypersensitivity immune reactions are classified into four types, according to the GellCoombs classification (Coombs and Gell 1968). Type I hypersensitivity reactions are considered
immediate hypersensitivity reactions. Symptoms present quickly, within minutes or a few hours
and include urticaria, angioedema, anaphylactic shock, and rhinitis. Type II hypersensitivity
reactions are antibody-mediated, and examples include thrombocytopenia and hemolytic anemia
(Descotes and Choquet-Kastylevsky 2001). Type III hypersensitivity reactions are immune
complex-mediated reactions, and examples include serum sickness and Arthus reaction (Justiz
Vaillant et al. 2020). Type IV hypersensitivity reactions are delayed reactions and include skin
reactions from plant resins, drugs, cosmetics, and environmental chemicals (Descotes and
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Choquet-Kastylevsky 2001). Delayed-type reactions take a minimum of 12-24 hours to develop
(Krouse et al. 2008), with most developing within 2-14 days after exposure (Descotes and
Choquet-Kastylevsky 2001; Warrington et al. 2011).
The side effects noted with Invisalign® material (hives, difficulty breathing, swollen lips
and tongue) are most closely related to type I (immediate hypersensitivity) and type IV (cellmediated delayed-type hypersensitivity). PBMCs stimulated with beta-lactam antibiotics
(antibiotics known to cause delayed-type reactions and immediate reactions) had increased
expression of IFN-γ (Lochmatter et al. 2009). When stimulated with nickel (a metal known to
cause delayed-type reactions), PBMCs did not increase IFN-γ or TNF-α, but there was an
increase in IL-4, which are associated more with Th2 cells and humoral immunity (Borg et al.
2000).
The rationale for this project was to document the cytokines expressed by PBMCs and
THP-1 monocytes challenged with Invisalign® plastic material. These cytokines are thought to be
involved in the Invisalign® material induced-immune response and subsequent side effects. This
research is innovative because there has been no research to date on the Invisalign® material’s
immune response. The primary impact of this study, if successful, would help to understand why
some individuals react to Invisalign® material, and the mechanism by which the immune
reactions are produced. This knowledge may help prevent unwanted reactions, identify who may
be susceptible, and possible treatment options.
The purpose of this study was to examine the expression pattern of cytokines (IL-1, TNFα, IL-6, IL-8, IL-12, IFN-γ, IL-10) when PBMCs and THP-1 monocytes are exposed to
Invisalign® material in vitro, using a sandwich enzyme-linked immunosorbent assay (ELISA)
technique multiplex flow cytometry.
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CHAPTER 2: LITERATURE REVIEW
2.1. Invisalign®
Invisalign® is a clear aligner system used to straighten teeth and has become a popular
treatment among orthodontists and patients alike. According to the Invisalign® website, over 8
million patients have been treated worldwide. Invisalign® was introduced in 1997 by Align
Technology (Santa Clara, California) as a more esthetic counterpart to traditional fixed
appliances. The more esthetic option has drawn more adults into orthodontic treatment (Kravitz et
al. 2009), but Invisalign® continues to develop products for even the youngest orthodontic
patients.
The Invisalign® clear aligner system is available to orthodontists and dentists to treat a
variety of malocclusions. The process starts by taking an impression or digital scan of the
patient's teeth and sending it to Align Technology. The computer-aided-design and computeraided- manufacturing (CAD-CAM) technology creates a treatment sequence that that is reviewed
by the doctor (Kravitz et al. 2009; Phan and Ling 2007). The clear aligners are then manufactured
and sent to the doctor who oversees patient treatment. Each aligner is designed to fit over the
teeth and is programmed to move the teeth about .25-.3 mm. Previously it was recommended that
the patient wear each tray for 14 days (Kravitz et al. 2009; Phan and Ling 2007), but currently,
many doctors are having their patients wear each tray for a shorter period, even 7 days. The
patient is advised to wear their trays for 20-22 hours per day, only taking them out to eat, brush,
or drink anything other than water (Phan and Ling 2007).
2.2. Side Effects
As with any treatment, Invisalign® treatment does come with side effects. One side effect
of treatment with both traditional fixed appliances and aligners is pain from tooth movement.
Although patients undergoing aligner treatment have less pain overall than those with fixed
appliances, their pain from aligners peaks during the first 24 hours and decreases until day 7
(White et al 2017). With less pain from treatment, Invisalign® patients also take fewer pain
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medications, such as Ibuprofen, than patients with traditional fixed appliances (White et al. 2017).
Other common side effects during Invisalign® aligner treatment include difficulty with speech
and swallowing, difficulty with chewing, food packing between teeth, mucosal irritation, sleep
disturbances, and TMJ problems (Miller et al. 2007; Nedwed and Miethke 2005; Pacheco-Pereira
et al. 2018; White et al. 2017). Poor oral hygiene during Invisalign® aligner wear can cause caries
and worsened periodontal health; although compared to traditional fixed appliances, patients
wearing aligners had better periodontal health status overall (Chhibber et al. 2018; Levrini et al.
2015).
2.2.1. MAUDE Database
To examine more serious adverse effects of Invisalign® aligners, Allareddy et al.
(2017) searched the Manufacturer and User Facility Device Experience (MAUDE) database from
2006-2016 for reports on Invisalign®. The MAUDE database is a United States Food and Drug
Administration (FDA) program that includes reports from manufacturers, health care professionals,
patients, and consumers. From November 1, 2006, to November 30, 2016, there were 173 medical
device reports regarding adverse effects from Invisalign® aligners. Difficulty of breathing was the
most common event reported (56 events). Other common reports included swollen tongue (31
reports), hives and itchiness (31 events), and anaphylaxis (30 events). Less common events were
blisters on the tongue (6 events) and swelling of gums (5 events). In 26% of reported events, the
treating doctor thought the event was very serious or life-threatening, with more serious events
occurring in the years 2014 through 2016. Because this database is not based on mandatory
reporting, the data may not be complete, accurate, or an actual result from the product itself
(Allareddy et al. 2017).
2.2.2. Case Reports
In 2017, Awosika et al. (2017) reported that a patient who, two days after starting
Invisalign® treatment, developed urticaria (hives) on her extremities, facial swelling, and burning
of the lips and oral mucosa. The patient had patch testing performed with an Invisalign® material
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sample and, at 96 hours, had a strong positive reaction that they deemed contact hypersensitivity
(Awosika et al. 2017).
A patient at the University of Nebraska Medical Center College of Dentistry sought
treatment for swelling and bleeding from the gums with no pain. She had been using Invisalign®
for the past 18 months and had previously had sores treated with Chlorhexidine. She presented with
generalized edematous gingival enlargement. A biopsy showed foreign body granulomatous
inflammation. She was treated with oral prednisone for three months to control the inflammation
(Narayana N, personal communication, May 1, 2020).
2.2.3. Biological Effects
There are very few studies that report on the effects of Invisalign® material at the cellular
level. Eliades et al. (2009) found no cytotoxic effects of Invisalign® material on gingival fibroblasts,
although Martina et al. (2019) reported a slight cytotoxic effect induced by the Invisalign®
SmartTrack® material (78.8% of cell viability). Invisalign® material does not induce estrogenic
effects (Eliades et al. 2009) and does not contain Bisphenol A (BPA) (Kotyk and Wiltshire 2013).
Premaraj et al. (2014) exposed oral keratinocytes to ground Invisalign® material and found that
cells treated with the material had metabolic inactivity and increased cell death compared to
controls. The cells also showed compromised membrane integrity, reduced contact, and reduced
mobility. This study demonstrates that Invisalign® material has a cytotoxic effect on keratinocytes
and compromises cell membrane integrity. The authors postulate this could be an avenue for
Invisalign® material components to enter the system and cause immune reactions (Premaraj et al.
2014).
2.3. SmartTrack® Material
In 2013, Align Technology launched its SmartTrack® material that was later patented in
2017. According to the company, SmartTrack® “delivers more gentle constant force to improve
control of tooth movements with Invisalign® clear aligners” (SmartTrack® 2020). The Invisalign®
website claims that SmartTrack® material straightens teeth faster and the trays are more
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comfortable to take on and off. Compared to the material before SmartTrack®, the patients who had
aligners made from SmartTrack® material had less pain for a shorter duration and increased overall
comfort (Bräscher et al. 2016).
According to the SmartTrack® Aligner Material safety data sheet, the material is a
multilayer aromatic thermoplastic polyurethane/copolyester. Although the specific components
and amounts are proprietary, the material safety data sheet contains multiple warnings for
diphenylmethane diisocyanate (MDI) as a component of the polyurethane. It warns that although
thermoplastic polyurethane is non-hazardous in normal conditions, if heated above the
decomposition temperature (492F), the MDI can be released and cause mucous membrane
irritation, shortness of breath, and asthma-like symptoms, among others (Material safety data sheet
2015). In 2004, Schuster et al. (2004) found that no byproducts were released from the Invisalign®
material when soaked in an ethanol-water solvent. They concluded, though, that because the trays
may be abraded within the mouth, this may affect the release of byproducts while being worn.
Others have hypothesized that the diphenylmethane diisocyanate (MDI) is the component of the
Invisalign® material that causes many of the adverse biologic reactions (Premaraj et al. 2014).
2.4. Isocyanates
Isocyanates are low molecular weight compounds that are used in the production of
polyurethanes. They contain one or more N=C=O groups that react with the hydroxyl groups from
other compounds to form polymer chains. Polyurethanes that contain MDI are used in many
industries, including automotive, clothing, paints, and medical care (Schuster et al. 2004; Wenk
and Ehrlich 2012).
2.4.1. Adverse Effects
Isocyanates have been known to cause asthma and allergic contact dermatitis, and many
reports have been in workplace settings (Aalto-Korte et al. 2012; Frick et al. 2003). One company
that produced laminate boards with an MDI-containing polyurethane lacquer had five employees
develop eczema on their hands and forearms that was consistent with allergic contact dermatitis
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(Frick et al. 2003). When tested for isocyanate allergy, workers in the motor vehicle, electronic,
and paint industries were most likely to react, with MDI being the component most associated with
a positive reaction (Aalto-Korte et al. 2012).
2.5. Immunology review
Because the biologic reactions seen in patients treated Invisalign® aligners are immunerelated, it is prudent to review basic immunology concepts elaborated in this research. Cells of the
immune system are derived from pluripotent stem cells in the bone marrow and differentiate first
into myeloid or lymphoid progenitor cells. Cells of the myeloid lineage include erythrocytes (red
blood cells), mast cells, thrombocytes (platelets), neutrophils, eosinophils, basophils, and
monocytes/macrophages (Figure 2.5). Neutrophils are highly motile cells and are one of the first
cells present at the site of inflammation; they work to ingest, kill, and digest pathogens. Eosinophils
are important in defending against parasitic infections and are common in cytotoxic
hypersensitivity reactions. Basophils are involved in the process of allergic inflammation; when
IgE attached to their surface binds with an antigen, basophils release histamine and heparin that is
contained within granules in the cytoplasm. Macrophages are derived from monocytes and both are
involved in phagocytosis and killing of microorganisms (Goldman and Prabhakar 1996).
Monocytes and macrophages also serve as antigen-presenting cells (APCs), which help activate
other immune system components, such as T cells, by their cell surface proteins called the major
histocompatibility complex (MHC). Other APCs include dendritic cells, B cells, fibroblasts, and
epithelial cells (Warrington et al. 2011).
Cells from the lymphoid lineage include T lymphocytes, B lymphocytes, and natural killer
cells (Goldman and Prabhakar 1996). T cells have an antigen-binding complex called the T cell
receptor (TCR) on its surface and is activated by the MHC-antigen complex on APCs. When
activated, T helper (Th) cells secrete cytokines or differentiate into cytotoxic T cells or. Cytokines
are proteins that aid in communication and interaction between cells (Warrington et al. 2011).
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Figure 2.5. Hematopoietic Differentiation of Cells. By A. Rad and M. Häggström. CC-BYSA 3.0 license.
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T helper cells have several subsets, including Th1 and Th2 cells. Th1 cells are important in cellmediated immunity, and Th2 cells aid B cells to produce antibodies.
The main purpose of B lymphocytes is antibody secretion after differentiation into plasma
cells. B lymphocytes also are involved in the processing and presenting of antigens to T cells
(Goldman and Prabhakar 1996). Lastly, natural killer (NK) cells kill tumor cells and cells infected
with viruses by releasing perforins and granzymes that induce apoptosis (Warrington et al. 2011).
2.6. Inflammation
There have not been any published reports to date to explain exactly the mechanism by
which Invisalign® material causes the symptoms previously described in certain individuals. The
symptoms are highly variable, from swollen gingiva to anaphylaxis, which leads to speculation as
to which mechanisms are at work. Inflammation is the immune system's protective mechanism
against tissue injury from many different stimuli, including pathogens or toxic compounds (Chen
et al. 2017). Although organ and stimuli specific, the first phase of acute inflammation is the
recognition of the stimuli mainly by macrophages and mast cells. This recognition activates
pathways that lead to the release of inflammatory mediators, including cytokines. Leukocytes,
mainly neutrophils, are extravasated from the blood to the site. Neutrophils are then activated, and
the content of their granules is released. Tissue damage can occur as the toxic substance does not
differentiate between the cause of the inflammation and the normal tissue (Medzhitov 2008). If the
immune system is successful in eliminating the cause, anti-inflammatory agents inhibit neutrophils
and recruit monocytes. Monocytes play a role in removing the damaged tissue and repairing the
site. When the initial immune response cannot eliminate the cause, macrophages and lymphocytes
enter, and the inflammation becomes chronic. If the macrophages cannot engulf the causative agent,
a granuloma may form (Medzhitov 2008). Granulomas are a type of chronic inflammation
characterized by macrophages, epithelioid cells, and multinucleated giant cells that surround the
causative agent to protect the body (Williams and Williams 1983).
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2.6.1. Cytokines
The role of cytokines in the inflammatory process can be either pro-inflammatory, antiinflammatory, or pleiotropic, meaning that they have multiple functions depending on the situation
(Borish and Steinke 2003). Each cytokine response varies with different stimuli and can interact in
a multitude of ways. Though there are hundreds of recognized cytokines, the following discussion
on cytokines is restricted to those most pertinent to the work reported in this thesis.
Interleukin (IL)-1 and tumor necrosis factor (TNF)-α work synergistically as proinflammatory cytokines (Dinarello 2000). IL-1 is produced by mononuclear phagocytes and
lymphocytes, among others, and contributes to inflammation by increasing PGE2 synthesis and
inducing fever, and aiding in T cells' proliferation. IL-1 also stimulates mast cells to release
histamine in acute inflammation (Feghali and Wright 1997). IL-1β, in the IL-1 family, is produced
mainly by monocytes and triggers fever and acute responses (Cameron and Kelvin 2000-2013), but
also plays a role in chronic inflammatory diseases (Dinarello 2000), including periodontitis.
Tumor necrosis factor (TNF)-α is a pro-inflammatory cytokine produced by mononuclear
phagocytes, activated lymphocytes, and natural killer cells. TNF's mechanism of action is known
to be similar to IL-1, and their effects together are synergistic. One difference is that TNF can have
a direct cytotoxic effect on cells, programming cell death. One of TNF-α's major stimulators is
lipopolysaccharide (LPS), an endotoxin from the outer-membrane of gram-negative bacteria
(Borish and Steinke 2003; Dinarello 2000).
IL-6 is another pro-inflammatory cytokine with similar fever-inducing functions as IL-1
and is produced mainly by mononuclear phagocytic cells, but also T and B lymphocytes and bone
marrow cells. IL-6 helps stimulate the differentiation of B lymphocytes into plasma cells. IL-1 and
TNF can induce the synthesis of IL-6, but IL-6 can also inhibit the production of those cytokines,
a function that is anti-inflammatory in nature (Borish and Steinke 2003).
IL-8 and IL-12 are also pro-inflammatory cytokines. IL-8 is a chemokine, a chemotactic
cytokine, responsible for neutrophil migration to the site of inflammation and activating neutrophil
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degranulation. It is produced by mononuclear phagocytes and T cells, among others (Borish and
Steinke 2003; Dinarello 2000). Its pro-inflammatory effects are seen in acute inflammation, such
as allergy, and also chronic inflammation (Feghali and Wright 1997), such as periodontal disease
(Finoti et al. 2017). IL-12 is produced by monocytes and macrophages, B cells, polymorphonuclear
neutrophils, and mast cells. It is involved in the differentiation cytotoxic T lymphocytes, natural
killer cells, and T helper cells into Th1 cells (Gee et al. 2009). IL-12p70 is the bioactive form when
two subunits, p35 and p40, combine (Gee et al. 2009; Kobayashi et al. 1989).
Another cytokine involved with Th1 cells is IFN-γ. IFN-, originally called Macrophage
activation factor, is produced by Th1 cells, NK cells, and cytotoxic T cells. It has antiviral activity
by inhibiting viral replication and also leads to cytotoxic T-cell development. IFN- is also
proinflammatory in that it can upregulate proinflammatory cytokines, such as TNF-a and IL-12,
and increases nitric oxide production from macrophages (Dinarello 2000; Mühl and Pfeilschifter
2003).
The outcomes of diseases can be dependent on the balance of pro-inflammatory vs. antiinflammatory cytokines. IL-10 is anti-inflammatory by suppressing production of IL-1, TNF, IFNγ and IL-12 (Dinarello 2007). IL-10 is produced by monocytes, T cells, and B cells (Borish and
Steinke 2003; Feghali and Wright 1997).
2.7. Hypersensitivity Reactions
Four types of hypersensitivity reactions were proposed by Coombs and Gell in 1968
(Coombs and Gell 1968). Type I reactions are considered immediate hypersensitivity reactions
and are the most common. These are commonly triggered by foods and environmental allergens,
such as pollen. Symptoms of these reactions include urticaria, angioedema, anaphylactic shock,
and rhinitis. These symptoms usually present quickly, within minutes or a few hours. In type I
reactions, IgE antibodies bind to mast cells, and when presented with the allergen, there is
degranulation of the mast cell cells and release of mediators, such as histamine (Descotes and
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Choquet-Kastylevsky 2001). Common treatments for this type of reaction include avoidance of
the allergen, desensitization, and antihistamines (Warrington et al. 2011).
Type II hypersensitivity reactions are antibody-mediated, and examples include
thrombocytopenia and hemolytic anemia. Cytotoxic antibodies, IgM and IgG, cause cell damage
by multiple mechanisms, including the direct activation of macrophages, neutrophils, and
eosinophils and the activation of the complement pathway. Type III hypersensitivity reactions are
immune complex-mediated reactions, and examples include serum sickness and Arthus reaction
(Justiz Vaillant et al. 2020). This occurs when antibodies such as IgM or IgG react with the
antigen and form immune complexes that can be deposited in blood vessels of various parts of the
body, including the joints and skin, kidney, lung. When complement is activated, it causes
inflammation and tissue injury (Descotes and Choquet-Kastylevsky 2001).
Type IV hypersensitivity reactions are delayed reactions and are unique because they do
not involve antibodies, as seen in the previous hypersensitivity reactions. This type of reaction
occurs when antigen-presenting cells encounter the antigen and present it to T cells; this causes
the T cells to differentiate and release cytokines, typically IFN-gamma and TNF. Type IV
reactions include skin reactions from plant resins, drugs, cosmetics, and environmental chemicals
(Descotes and Choquet-Kastylevsky 2001). Granulomatous and giant cell reactions are also
considered type IV reactions. Delayed-type reactions take a minimum of 12-24 hours to develop
(Krouse et al. 2008), with most developing within 2-14 days after exposure (Descotes and
Choquet-Kastylevsky 2001; Warrington et al. 2011). Treatment for type IV reactions includes the
removal of the stimulus and possibly the use of corticosteroids (Warrington et al. 2011).
The adverse biological effects previously noted from Invisalign® material look most
similar to type I and type IV reactions. The reports of anaphylaxis and difficulty breathing are
similar to type I immediate hypersensitivity, and the swollen gums/granulomatous inflammation
are type IV delayed-type hypersensitivity. Although, some reported side effects could be either
type depending on the time of onset of symptoms and the mechanism of the immune response.
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For example, difficulty breathing is be associated with type 1 anaphylactic reactions but could
also be attributed to inflammation in the oropharynx in a type IV reaction, especially if onset of
symptoms is delayed. In this study we looked at a variety of cytokines, none of which will give
information on a type 1 reaction mechanism. IL-4 expression would give more information on the
possible type 1 reaction but was not included in the Human Inflammation Panel 1 from
BioLegend. Therefore, the cytokines in this study focused on possible cytokines in type IV
hypersensitivity reactions and those that may be induced with isocyanate stimulation.
2.7.1. Specifics of Type IV Hypersensitivity Reactions
In delayed reactions, the antigen is recognized by an APC, which presents the antigen to
the T helper cell, and they bind together. In the tuberculin reaction, a well-known Type-IV
reaction, the binding causes a release of cytokines from the APC, including IL-12 and IL-18.
These cytokines, along with interferon-gamma (IFN-γ) from NK and Th1 cells, help differentiate
the T helper cell into Th1 cells. Th1 cells are known to release IL-2 and IFN-γ. These cytokines
can activate macrophages, producing IL-8 IL-1, IL-6, and TNF-α, among others. This contributes
to the inflammatory reaction by recruiting neutrophils, monocytes, and lymphocytes to the site
and will contribute to granulomatous inflammation if a foreign substance is involved (Kobayashi
et al. 2001).
When T cells differentiate into Th2 cells via IL-4 release, the Th2 cells are known to
release IL-4, IL-5, IL-6, IL-10 and IL-13. Th2 cells and these cytokines contribute to humoral
immunity (compared to cell-mediated with Th1 cells) and allergic responses (Kobayashi et al.
2001). Lochmatter et al. (2009) found that PBMCs exposed to beta lactam and sulfonamide drugs
(antibiotics known to cause delayed-type reactions and immediate reactions) had a delayed-type
reaction and increased IL-5, IFN-γ, IL-13, and IL-2. Borg et al. (2000) used nickel to stimulate
PBMCs, which is a substance known to cause delayed-type contact dermatitis. Nickel ions bind to
larger proteins, including MHC protein and the subsequent haptens and modified MHC of
dendritic cells. This modification of the binding surface of the MHC activates T cell proliferation
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and differentiation. Upon re-exposure to nickel, the hapten-specific T cells are once again
activated, leading to the production of inflammatory cytokines and development of the
characteristic skin lesion (Saito et al. 2016, Wang and Dai 2013). Interestingly, Borg et al. (2000)
did not find an increase in IFN-γ or TNF-α, but did find an increase in IL-4 and IL-5, which are
associated more with Th2 cells and humoral immunity.
2.8. Immunologic Reactions from Isocyanates
Mishra et al. (2008) stimulated human lymphocytes with methyl isocyanate and found a
dose and time-dependent increase in IL-8, IFN-γ, TNF, IL-1β, IL-6 and IL-12p70. Another study
found that PBMCs exposed to diisocyanate antigen had increased production of IL-8 and TNF-α,
but no significant increase of typical Th1 or Th2 cytokines IL-4, IL-5, or IFN-γ. They
hypothesized that TNF-α is chemotactic for neutrophils and monocytes and that IL-8 can be
induced in monocytes by stimuli, including TNF-α (Lummus et al. 1998).
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CHAPTER 3: RESEARCH HYPOTHESIS & SPECIFIC AIMS
3.1. Statement of the Problem
Invisalign® clear aligners cause adverse side effects, such as hives, swelling of the lips
and tongue, and difficulty breathing, in some patients. The mechanisms underlying these
immune-mediated side effects are unknown. The immune response and subsequent expression of
cytokines from cells exposed to Invisalign® material have yet to be studied in detail. This
information will help better understand how these adverse reactions occur, who might be
susceptible, and how they might be treated and/or prevented.
3.2. Central Research Hypothesis
The central research hypothesis is that there will be an increased cytokine expression
when cells of the immune system are exposed to Invisalign® material in vitro.
3.3. Specific Aims
1) To determine which, if any, cytokines are expressed in immune cells exposed to
Invisalign® material in vitro.
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CHAPTER 4: MATERIALS & METHODS
4.1. Study Design
This descriptive study is an in vitro evaluation of the cytokine production of immune
cells (PBMCs and THP-1 human monocytes) after cell culture with various conditions and
Invisalign® material eluate addition. The cytokines were profiled using a BioLegend
LEGENDplex™ sandwich ELISA technique. Four separate cell culture and assays were
completed, and the results reported. Because this is a pilot study, the experimental design was
changed multiple times after troubleshooting errors from previous experiments.
4.2. Invisalign® Material and Eluate Preparation
The Invisalign® material and eluate preparation protocols were based on the procedures
reported by Premaraj et al. (2014). The Invisalign® aligners were ordered in 2017 by the
University of Nebraska Medical Center College of Dentistry in Lincoln, NE, to treat an
orthodontic patient. The treatment plan was changed mid-treatment, and new aligners were
ordered; therefore, the remainder of the aligners were available for this research. The plastic was
ground into particles with a 12-inch half-circle, flat-bottom file. The size and distribution of the
particles were measured with the technique of dynamic light scattering (DLS) using a Zetasizer
system (Malvern Panalytical). The temperature and scattering angle were set at 25°C and 90°,
respectively.
To prepare the eluate, 0.1 g of particles were soaked in 1 mL of artificial saliva
(Fusayama/Mayer solution, not stabilized, Pickering Laboratories, Mountain View, CA) at 37°C
for 24 hours, 48 hours, 72 hours, one week and two weeks. To collect the eluate, the material was
centrifuged at 1500 rpm for 10 minutes. The supernatant was collected and stored at 2°C until
use. The eluate preparation methods were the same across all experiments.
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4.3. Experiment 1: Pooled PBMCs
4.3.1. Cell Culture
Pooled cryopreserved PBMCs were purchased from Zenbio (Research Park Triangle,
NC) for this experiment. PBMCs were chosen because they contain many cells of the immune
system and are used widely in immunological research (Pourahmad and Salimi 2015; Lummus et
al. 1998). There were four Caucasian donors in the purchased PBMC lot, a mix of male/female,
with an average age of 61. The percentage of positive cells was 43.7% T cells, 32.2% helper T
cells, 8.1% cytotoxic T cells, 11.3% B cells, 28% monocytes, and 9.4% NK cells. The cells were
thawed and prepared according to the Zenbio recommended protocol. The cells were plated at
25x104 cells/well in a 96 well plate and cultured in RPMI-1640 medium (Sigma-Aldrich, St.
Louis, MO) with 10% fetal bovine serum (FBS) and 1% of L-glutamine-penicillin-streptomycin
solution (Sigma-Aldrich, St. Louis, MO). The negative controls contained only cells and media,
and the saliva negative control had the addition of 43 μL of artificial saliva (Pickering
Laboratories, Mountain View, CA). The saliva control was included so any reaction to the
Invisalign® material eluate could be solely attributed to the Invisalign® material. The Invisalign®
material sample wells included 43 μL of the 2-week Invisalign® material eluate. The positive
controls were stimulated with 500ng/mL E. coli lipopolysaccharide (LPS) (Sigma-Aldrich, St.
Louis, MO). All wells had a total of 250 μL. Cells were cultured in a 5% CO2 incubator at 37 °C
for 24 and 72 hours. The samples were collected, transferred to microcentrifuge tubes, and
centrifuged at 1500 rpm for 10 minutes. The supernatant was collected and stored at -20°C until
use.
4.3.2. LEGENDplex™ Assay
This assay was performed using a LEGENDplex™ Multi-Analyte Flow Assay with a
custom 3-plex from the Human Inflammation 1 kit, including IL-8, IL-6, and TNF-α (BioLegend,
Cat. No. 740809, San Diego, CA).
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4.3.2.1 Assay Preparation
The assay preparation steps, and assay procedures were followed as described in the
assay manual. The antibody-immobilized beads were vortexed for 3 minutes to resuspend the
beads. The wash buffer was prepared by bringing to room temperature and diluting with 475 mL
deionized water.
To prepare the standards, the standard cocktail was reconstituted with 250 μL of Assay
Buffer and used as the top standard, C7. A serial 1:4 dilution was prepared for standards C6-C1.
Assay buffer was used as the 0 pg/mL standard (C0).
4.3.2.2. Assay Procedure
This assay was performed using a V-bottom plate, and the directions were followed
accordingly from the assay manual (Figure 4.3.2.2). All samples and standards were plated in
duplicate in a vertical configuration for easy data acquisition and analysis. The standard wells
included 25 μL of standard with 25 μL of assay buffer. The sample wells had 25 μL of sample
with 25 μL of assay buffer. The samples were not diluted before adding to wells. The mixed
beads were vortexed again for 30 seconds before adding 25 μL to each well. The total final
volume in each well was 75 μL. The plate was sealed with a plate sealer and covered in aluminum
foil before shaking on a plate shaker at 800rpm for 2 h at room temperature.
After the incubation time, the plate was centrifuged at 1050 rpm for 5 minutes, using a
swinging bucket rotator with microplate adaptor. After centrifugation, the supernatant was
dumped by quickly inverting and flicking the plate in one continuous and forceful motion.
Next, the plate was washed with 200 μL of wash buffer and the centrifugation steps were
completed again. Then, 25 μL of detection antibodies were added to each well, and the plate was
incubated again for 1 hour. After this, 25 μL of Streptavidin –PE (SA-PE) was added to each
well, without prior washing, and incubated for another 30 minutes.
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Figure 4.3.2.2. BioLegend LEGENDplex™ V-bottom Plate Procedures.
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The plate was then washed two more times. Finally, 150 μL of wash buffer was added to
each well, and the beads were resuspended by pipetting.
4.3.2.3 Flow Cytometry and Data Analysis
The samples were read on a flow cytometer on the same day as the assay was performed
using a CytoFLEX LX (Beckman Coulter). The settings were configured according to the
directions in the LEGENDplex™ manual. The data was analyzed using BioLegend’s
LEGENDplex™ cloud-based data analysis software, Qognit, found on the BioLegend website.
4.4. Experiment 2: Individual Donor PBMCs
4.4.1. Cell Culture
For this experiment, cryopreserved PBMCs from three separate donors were purchased
from Precision for Medicine (Frederick, MD). Donor 1 was a 37-year-old Caucasian male
smoker. Donor 2 was a 26-year-old Latino male nonsmoker and donor 3 was a 53-year-old Latino
male nonsmoker. The donors were not taking any medications. Cells were thawed and prepared
as described by the Precision for Medicine protocols. For this experiment, the FBS was heatinactivated by heating at 56°C for 30 minutes. The cell culture methods were the same as
Experiment 1, with the only change being three separate donors instead of pooled cells.
4.4.2. LEGENDplex™ Assay
The LEGENDplex™ assay for this experiment was performed using the LEGENDplex™
kit, cytokines, procedures, and flow cytometry as previously described.
4.5. Experiment 3: Individual Donor PBMCs
4.5.1. Cell Culture
For this experiment, cryopreserved PBMCs from three different donors were purchased
from Precision for Medicine (Frederick, MD). Donor 1 was a 35-year-old Caucasian male,
smoker, taking no medications. Donor 2 was a 31-year-old Caucasian woman, nonsmoker, taking
Zoloft and Bupropion. Donor 3 was a 35-year-old Caucasian male, nonsmoker, taking Lisinopril
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and Lovastatin. Cells were thawed and prepared as described by the Precision for Medicine
protocols. The cell culture methods were the same as Experiment 2, with the only change being
that the LPS was vortexed for 15 minutes before use, and positive controls included 1 μL/mL of
LPS and 500 ng/mL E. coli LPS.
4.5.2. LEGENDplex™ Assay
The LEGENDplex™ assay for this experiment was performed using the LEGENDplex™
kit, cytokines, procedures, and flow cytometry as previously described.
4.6. Experiment 4: THP-1 Human Monocyte Cell Line
4.6.1. Cell Culture
The THP-1 human monocyte cell line (ATCC® TIB-202™) was used in this experiment
and cultured according to the protocol provided by Dr.Toshihisa Kawai at Nova Southeastern
University College of Dental Medicine, where the cells were obtained. THP-1 is a human
monocyte cell line from a patient with childhood acute monocytic leukemia (Tsuchiya et al.
1980). This cell line is a model for human monocytes and is used in research as a model for
immune reactions and inflammation in vitro (Bosshart and Heinzelmann 2016; Yang et al. 2016).
The cells were plated at 25x104 cells/well in a 96 well plate and cultured in RPMI-1640 medium
(ATCC) with 10% of heat-inactivated FBS (Gibco, ThermoFisher Scientific, Waltham, MA) and
1% of penicillin-streptomycin solution. The negative controls contained only cells and media and
the saliva controls had the addition of 50 μL artificial saliva (Pickering Laboratories, Mountain
View, CA). The Invisalign® material wells included 50 μL of the 72-hour Invisalign® material
eluate. The positive control samples were stimulated with 500 ng/ml P. gingivalis LPS. P.
gingivalis LPS is more relevant to intraoral conditions, although it is atypical and structurally
different from E. coli LPS (Holden et al. 2014). All wells had a total of 200 μL. Cells were
cultured in a 5% CO2 incubator at 37 °C for 24 and 72 hours. The samples were collected,
transferred to microcentrifuge tubes, and centrifuged at 1500 rpm for 10 minutes. The supernatant
was collected and stored at -20°C until use.
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4.6.2. LEGENDplex™ Assay
This assay was performed using a LEGENDplex™ Multi-Analyte Flow Assay Kit with a
custom 7-plex from the Human Inflammation 1 kit, including IL-8, IFN-γ, IL-10, IL-12p70, IL1β, IL-6, TNF-α (BioLegend, Cat. No. 740809, San Diego, CA).
4.6.2.1. Assay Procedure
The assay materials were prepared as previously described. This assay was performed
using a filter plate instead of a V-bottom plate, and the directions were followed accordingly
(Figure 4.6.2.1.). To pre-wet the filter plate, 100 μL of wash buffer was added to each well and let
sit for 1 minute. The vacuum was then applied (not exceeding 10" Hg of vacuum) until wells
were drained (about 5-10 seconds) and excess buffer blotted out. All samples and standards were
plated in duplicate in a vertical configuration for easy data acquisition and analysis. The standard
wells included 25 μL of standard with 25 μL of assay buffer. The sample wells had 25 μL of
sample with 25 μL of assay buffer. The samples were not diluted before adding to wells. The
mixed beads were vortexed for 30 seconds before adding 25 μL to each well; the total volume in
each well was 75 μL. The plate was sealed with a plate sealer and covered in aluminum foil
before shaking on a plate shaker at 500 rpm for 2 h at room temperature.
Next, the plate was vacuumed, as previously described. Then 200 μL of wash buffer was
added to each well, and another vacuum step was completed to remove the wash buffer. This
washing step was repeated. Then, 25 μL of detection antibodies were added and the plate was
incubated again on the shaker at 500rpm for 1 h. After this, 25 μL of Streptavidin –PE (SA-PE)
was added to each well, without prior vacuuming, and incubated for another 30 minutes on the
plate shaker.
The plate was then vacuumed and washed two times. Finally, 150 μL of wash buffer was
added to each well, and the beads were resuspended on a plate shaker for 1 minute.
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4.6.2.2. Flow Cytometry and Data Analysis
The samples were read on a BD Fortessa X20 (BD Biosciences) flow cytometer on the
same day as the assay and configured according to the directions in the LEGENDplex™ manual.
The data was analyzed as previously described with the analysis software.
4.7. Statistical Analysis
The data for each duplicate were averaged and the standard error was calculated. The
data is reported as the mean concentration in pg/mL with standard error. A Mann-Whitney U test
was conducted with the saliva control data and Invisalign® material sample data for IL-8 from
experiments 2-4 (α < 0.05, two-tailed).
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Figure 4.6.2.1. BioLegend LEGENDplex™ Filter Plate Procedures.
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CHAPTER 5: RESULTS
5.1. Particle Size
The size and distribution of the Invisalign® material particles used for all experiments in
this study were measured with the technique of dynamic light scattering using a Zetasizer system
(Malvern Panalytical). The particle report is shown in Table 5.1. and the size distribution graph in
Figure 5.1. The Z-average radius of the particles was between 502.9 and 873.5 nm. The smallest
particles had a mean radius of 0.71 nm, and the largest detected had a mean radius of 552.6 nm.
5.2. Experiment 1: Pooled PBMCs
The results of the experiment 1 assay are shown in Table 5.2. The standard curves are
included in Figure 5.2.
5.2.1. TNF-α
For the samples collected after 24 hours, the negative control (cells alone in media) and
saliva control (addition of artificial saliva) samples had mean TNF-α concentrations of 82.56 and
18.52 pg/mL, respectively. The Invisalign® material sample induced slightly higher TNF- α, at
378.71 pg/mL. The LPS positive control stimulated a mean concentration of 1814.27 pg/mL of
TNF- α (Figure 5.2.1).
For the samples collected at 72 h culture, the negative control and saliva control had
mean TNF-α concentrations of 22.77 and 10.49 pg/mL, respectively. The Invisalign® material
sample induced a TNF-α concentration of 128.41 pg/mL, and the LPS positive control sample
had TNF-α at 1324.33 pg/mL. The 72 h culture values were less than at 24 h, with the Invisalign®
material sample almost 3x lower at 72 h than 24 h (128.41 vs. 378.61 pg/mL TNF- α).
5.2.2. IL-6
The values for IL-6, at 24 h and 72 h, were very high compared to the assay standards
(Table 5.2). The negative control at 24 h had 49,0176.53 pg/mL IL-6 and at 72 h had 51,980.48
pg/mL IL-6. Because all values are higher than the highest standard, the values cannot be
determined accurately for the various samples.
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Sample

Z-Ave
(r.nm)

Pk 1 Mean Int
(r.nm)

Pk 2 Mean Int
(r.nm)

Pk 1 Area Int
(%)

Pk 2 Area Int
(%)

1

873.5

519

0

100

0

2

545.3

549.1

0.72

90.5

9.5

3

502.9

552.6

2.28

86.8

13.2

Table 5.1. Dynamic Light Scattering Particle Report. The DLS report shows the average
radius of the Invisalign® particles ranged from 502.9-873.5 (Z-Ave). Some nanoparticles were
found in the sample with a radius of smaller than 3 nm.

Figure 5.1. Particle Size Distribution. The red line denotes the first sample, the blue line the second, and the green line the third
sample.
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5.2.3. IL-8
Similar to IL-6, the values for IL-8 were all higher than the highest standard. The
negative controls at 24 h and 72 h were 16,054.63 pg/mL IL-8 and 16,007.56 pg/mLIL-8,
respectively.
Since higher levels of cytokine expression in the first experiment with pooled PBMCs
was due to MHC protein incompatibility, the decision to repeat the experiment with single donor
PBMCs was made. In addition, heat inactivation of FBS was also performed to eliminate the
unwanted influence of cytokine activation from sources other than Invisalign, such as
complement components.
5.3. Experiment 2: Individual Donor PBMCs
The results of the second experiment assay are shown in Table 5.3. The standard curves
are included in Figure 5.3.
5.3.1. TNF-α
For donor 1, the TNF- α values for the negative control, saliva control, and Invisalign®
material sample were all very low at 0.57 pg/mL. The LPS control induced only slightly higher
TNF- α at 1.01 pg/mL. For donor 2, all samples had TNF-α concentrations of 0.57 pg/mL. Donor
3 also had negative control, saliva control, and Invisalign® material samples of 0.57 pg/mL of
TNF- α. The LPS control for donor 3 induced 0.68 pg/mL TNF- α. The LPS positive control did
not induce TNF- α in any donor, therefore no conclusions can be drawn about Invisalign®
material stimulation on the cells.
5.3.2. IL-6
For donor 1, the negative control and saliva control both had IL-6 concentrations of 0.32
pg/mL. The Donor 1 Invisalign® material and LPS induced concentrations of IL-6 at 0.78 and
9.01 pg/mL, respectively. For donor 2, the negative control had 0.32 pg/mL IL-6, saliva control
had 0.34 pg/mL IL-6, the Invisalign® material induced 0.38 pg/mL IL-6, and the LPS induced
3.03 pg/mL IL-6.
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Figure 5.2. Experiment 1
Standard Curves.
Concentration (pg/mL) vs.
MFI standard curve for A.
TNF-α. B. IL-6. and C. IL-8.
The standard cocktail was
reconstituted with 250 μL of
Assay Buffer and used as the
top standard, C7. A serial 1:4
dilution was prepared for
standards C6-C1. Assay
buffer was used as the 0
pg/mL standard (C0). All
standards were plated in
duplicate.
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Sample
Negative control
Saliva control
Invisalign®
LPS control

Negative control
Saliva control
Invisalign®
LPS control

TNF-α

IL-6

24 hours
82.68 ± 2.015
49076.53 ± 1274.48

IL-8
16054.63 ± 928.285

18.52 ± 3.18

51582.75 ± 19861.315

15766.58 ± 2063.125

378.61 ± 31.715

261748.17 ± 31186.705

17427.61 ± 857.3

1814.27 ± 212.945

288051.99 ± 2268.99

17412.53 ± 1143.06

72 hours
22.77 ± 1.33
51980.48 ± 772.94

16007.56 ± 768.92

10.49 ± 1.015

103471.56 ± 9480.24

20387.32 ± 373.015

128.41 ± 31.325

337863.20 ± 20851.505

15636.57 ± 904.535

1324.33 ± 110.745

210454.90 ± 8369.23

17612.92 ± 285.95

Table 5.2. Mean Cytokine Expression of Pooled PBMCs, Experiment 1. Mean cytokine
expression in pg/mL of pooled PBMCs cultured for 24 or 72 hours with different culture
conditions. The negative control has no additive, the saliva control has only artificial saliva
added, the Invisalign® sample is the addition of Invisalign® eluate, and the LPS control has 500
ng/ml LPS. Values shown are the mean of the duplicates reported with standard error.
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Concentration (pg/mL)

TNF-α
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1400
1200
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Negative control

Saliva control
24 hours

Invisalign

LPS control

72 hours

Figure 5.2.1. Mean TNF-α Concentration of Pooled PBMCs, Experiment 1. TNFalpha concentration in pg/mL of pooled PBMCs cultured for 24 or 72 hours with
different culture conditions. The negative control has no additive, the saliva control has
only artificial saliva added, the Invisalign® sample is the addition of Invisalign® elute,
and the LPS control has 500 ng/ml LPS. Values shown are the mean of the duplicates
with standard error.
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5.3.3. IL-8
For donor 1, the negative control and saliva control were 7.97 pg/mL IL-8 and 6.87
pg/mL IL-8, respectively. The Invisalign® material induced an IL-8 concentration of 63.85
pg/mL, and the LPS induced 138.34 pg/mL IL-8. Donor 2 had a baseline control of 1.56 pg/mL
IL-8 and saliva control at 5.20 pg/mL IL-8. The Invisalign® material induced an IL-8
concentration of 2.16 pg/mL, and the LPS positive control induced an IL-8 concentration of 18.21
pg/mL. Donor 3 negative and saliva controls samples had IL-8 concentrations of 4.23 pg/mL and
2.75 pg/mL, respectively. The Invisalign® material induced an IL-8 concentration of 5.37 pg/mL,
and LPS an IL-8 concentration of 27.41 pg/mL (Figure 5.3.2).
5.4. Experiment 3: Individual donor PBMCs
The results of the third experiment with individual donor PBMCs are shown in Table 5.4.
The standard curves for this assay can be seen in Figure 5.4. The duplicates for the fourth
standard, especially for IL-6 and IL-8, are widely varied.
5.4.1. TNF-α
For TNF-α, donor 1 had negative and saliva control sample concentrations of 67.04
pg/mL and 162.95 pg/mL, respectively, of TNF- α. The Invisalign® induced a slightly higher
concentration of TNF-α at 224. 11 pg/mL, while LPS-induced TNF-α was very high at 20,104.32
pg/mL. Donor 2 had TNF-α concentrations of 37.01 pg/mL for all samples, except for the saliva
control at 55.355 pg/mL TNF- α. For donor 3, the negative control had a TNF-α concentration of
401.99 pg/mL. The Invisalign® material induced 185.10 pg/mL TNF-α and the 1μg/ml and
500ng/mL LPS controls induced TNF-α concentrations of 13,576.61 pg/mL and 17,717.88pg/mL,
respectively (Figure 5.4.1).
5.4.2. IL-6
For donor 1, the negative and saliva controls had an IL-6 concentration of 69.37 pg/mL
and 117.65 pg/mL, respectively. The Invisalign® material induced an IL-6 concentration of
320.15 pg/mL, and the LPS induced 10,000 pg/mL IL-6. Donor 2 negative and saliva controls
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Figure 5.3. Experiment
2 Standard Curves.
Concentration (pg/mL)
vs. MFI standard curve
for A. TNF-α. B. IL-6. C.
IL-8. The standard
cocktail was reconstituted
with 250 μL of Assay
Buffer and used as the top
standard, C7. A serial 1:4
dilution was prepared for
standards C6-C1. Assay
buffer was used as the 0
pg/mL standard (C0). All
standards were plated in
duplicate.
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Sample
Negative control

TNF-α
Donor 1
0.57 ± 0

IL-6

IL-8

0.32 ± 0

7.97 ±0

Saliva control

0.57 ± 0

0.32 ± 0

6.87 ± 0.31

Invisalign®

0.57 ± 0

0.78 ± 0.39

63.85 ± 47.25

1.01 ± 0.44

9.01 ± 7.27

138.34 ± 109.22

0.32 ± 0

1.56 ± 0.38

LPS control

Negative control

Donor 2
0.57 ± 0

Saliva control

0.57 ± 0

0.34 ± 0.02

5.20 ± 3.06

Invisalign®

0.57 ± 0

0.38 ± 0.07

2.16 ± 1.82

LPS Control

0.57 ± 0

3.03 ± 0.49

18.21 ± 5.87

Negative control

Donor 3
0.57 ± 0
0.435 ± 0.12

4.23 ± 2.73

Saliva control

0.57 ± 0

0.77 ± 0.45

2.75 ± 0.49

Invisalign®

0.57 ± 0

0.65 ± 0.33

5.37 ± 0.18

0.68 ± 0.12

1.38 ± 0.95

27.41 ± 15.72

LPS control

Table 5.3. Mean Cytokine Expression of Three Individual Donor PBMCs,
Experiment 2. Mean cytokine expression in pg/mL of three individual donor
PBMCs cultured for 24 hours with different culture conditions. The negative
control has no additive, the saliva control has only artificial saliva added, the
Invisalign® sample is the addition of Invisalign® eluate, and the LPS control
has 500 ng/ml LPS. Values shown are the mean of the duplicates. Values
shown are the mean of the duplicates reported with standard error.
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IL-8
200

Concentration (pg/mL)

180
160
140
120

Negative control

100

Saliva control

80

Invisalign

60

LPS control

40
20
0
Donor 1

Donor 2

Donor 3

Figure 5.3.2. Mean IL-8 Concentration of Individual Donor PBMCs, Experiment
2. Mean IL-8 concentration in pg/mL of three individual donor PBMCs cultured for 24
or 72 hours with different culture conditions. The negative control has no additive, the
saliva control has only artificial saliva added, the Invisalign® sample is the addition of
Invisalign® elute, and the LPS control has 500 ng/ml LPS. Values shown are the mean
of the duplicates with standard error.
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were 29.71 pg/mL IL-6 and 45.54 pg/mL IL-6, respectively. The Invisalign® material induced an
IL-6 concentration of 40.96 pg/mL and LPS induced 18.85 pg/mL IL-6. Donor 3 negative control
concentration of IL-6 was 88.51 pg/mL, and the Invisalign® material induced 345.02 pg/mL IL-6.
The LPS positive controls (1μg/ml and 500ng/mL) both induced 10,0000 pg/mL IL-6 (Figure
5.4.1.).
5.4.3. IL-8
For IL-8, Donor 1 had a negative control of 1,626.53 pg/mL IL-8 and a saliva control of
2,580.65 pg/mL IL-8. Donor 1 also had an Invisalign® material- induced IL-8 concentration of
6,463.85 pg/mL. The LPS for Donor 1 induced 14,205.53 pg/mL IL-8. Donor 2 had negative and
saliva control IL-8 concentrations of 110.11pg/mL and 125.68 pg/mL, respectively. Donor 2
Invisalign® material induced 122.64 pg/mL IL-8 and LPS induced 71.16 pg/mL IL-8. Donor 3
had a negative control concentration of IL-8 of 2,212.68 pg/mL and a saliva control of 8,256.08
pg/mL IL-8. The 1μg/mL LPS and 500ng/mL LPS induced 44,767.21 pg/mL and 12,319 pg/mL,
respectively, of IL-8 (Figure 5.4.3). Therefore, the lower 500ng/mL LPS concentration was not
the cause for low positive control in the previous experiment. The negative control samples also
had high concentrations for this experiment.
Due to the inconsistent results obtained from the individual donor PBMCs, the decision
was made to use the THP-1 monocyte cell line for further experiments.
5.5. Experiment 4: THP-1 cells
The results from the fourth cell culture and assay of THP-1 cells are shown in Table 5.5.
and Figure 5.5.1. The standard curves for the assay are shown in Figure 5.5.
5.5.1. IL-1β
At 24 hours, the negative and saliva controls of THP-1 cells had concentrations of IL-1β
of 26.16 and 23.02 pg/mL, respectively. The 1:1 Invisalign® material and Invisalign® material
samples induced concentrations of IL-1 β at 12.75 pg/mL and 461.83pg/mL, respectively. The
LPS positive control induced IL-1β at 14.65 pg/mL.
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Figure 5.4. Experiment 3
Standard Curves. A.
Concentration (pg/mL) vs.
MFI standard curve for A.
TNF-α. B. IL-6 and C. IL-8.
The standard cocktail was
reconstituted with 250 μL of
Assay Buffer and used as the
top standard, C7. A serial 1:4
dilution was prepared for
standards C6-C1. Assay
buffer was used as the 0
pg/mL standard (C0). All
standards were plated in
duplicate.
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Sample
Negative control
Saliva control
Invisalign

®

LPS control
Negative control
Saliva control
Invisalign

®

LPS Control

TNF-α
Donor 1
67.04 ± 1.32

IL-6

IL-8

69.37 ± 1.31

1626.53 ± 249.19

162.95 ± 47.85

117.65 ± 22.67

2580.65 ± 961.36

224.11 ± 108.61

320.15 ± 98.95

6463.85 ± 2318.58

20104.32 ± 1697.94

10000.00 ± 0

14205.33 ± 248.20

29.71 ± 5.48

100.11 ± 3.44

55.36 ± 18.34

45.54 ± 13.32

125.68 ± 21.87

37.01 ± 0

40.95 ± 2.79

122.64 ± 1.04

37.01 ± 0

18.85 ± 0.22

71.16 ± 1.79

88.51 ± 0.75

2212.68 ± 84.12

Donor 2
37.01 ± 0

Negative control

Donor 3
401.99 ± 1.30

Invisalign®

185.10 ± 3.40

345.02 ± 2.25

8256.08 ± 367.07

LPS 1μg/ml control

13576.61 ± 34.13

10000.00 ± 0

44767.21 ± 24695.57

LPS 500ng/ml control

17717.88 ± 522.9

10000.00 ± 0

12319.75 ± 1911.73

Table 5.4. Mean Cytokine expression of three individual donor PBMCs, Experiment 3.
Mean cytokine expression in pg/mL of three individual donor PBMCs cultured for 24 hours
with different culture conditions. The negative control has no additive, the saliva control has
only artificial saliva added, the Invisalign® sample is the addition of Invisalign® eluate, and
the LPS control has 500 ng/ml LPS. Values shown are the mean of the duplicates reported
with standard error.
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TNF-α
5000

Concentration (pg/mL)

4500
4000
3500

Negative control

3000

Saliva control

2500

Invisalign

2000

LPS 500ng

1500

LPS 1 ug

1000
500
0
Donor 1

Donor 2

Donor 3

IL-6
5000

Concentration (pg/mL)

4500
4000
3500

Negative control

3000

Saliva control

2500

Invisalign

2000

LPS 500ng

1500

LPS 1 ug

1000
500
0
Donor 1

Donor 2

Donor 3

Figure 5.4.1. Mean TFN-α and IL-6 Concentration of Individual Donor PBMCs,
Experiment 3. Mean TNF-α and IL-6 concentration in pg/mL of three individual donor
PBMCs cultured for 24 or 72 hours with different culture conditions. The negative control has
no additive, the saliva control has only artificial saliva added, the Invisalign® sample is the
addition of Invisalign® elute, and the LPS control has 500 ng/ml LPS or 1μg/mL LPS. Values
shown are the mean of the duplicates with standard error.
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IL-8
16000

Concentration (pg/mL)

14000
12000
Negative control

10000

Saliva control
8000

Invisalign

6000

LPS 500ng

4000

LPS 1 ug

2000
0

Donor 1

Donor 2

Donor 3

Figure 5.4.3. Mean IL-8 Concentration of Individual Donor PBMCs, Experiment 3.
Mean IL-8 concentration in pg/mL of three individual donor PBMCs cultured for 24 or 72
hours with different culture conditions. The negative control has no additive, the saliva
control has only artificial saliva added, the Invisalign® sample is the addition of Invisalign®
elute, and the LPS control has either 500 ng/ml LPS or 1μg/mL LPS. Values shown are the
mean of the duplicates with standard error.
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At 48 hours, the negative and saliva controls had 3.27 pg/mL and 4.09 pg/mL
concentrations of IL-1β. The 1:1 Invisalign® material sample induced 12.15 pg/mL IL-1β, and the
Invisalign® material induced a concentration of 958.42 pg/mL IL-1β. The concentration of IL-1β
in the LPS control was 5.06 pg/mL.
5.5.2. IFN-γ
At both 24 and 48 hours, the concentration of IFN-γ from THP-1 cells for all samples
was 4.71 pg/mL. There was no variation in samples. The minimum detectible concentration of
IFN-γ in the assay is 1.6 pg/mL.
5.5.3. TNF-α
At 24 hours, the concentration of TNF-α for the negative and saliva controls was 6.95
pg/mL and 6.91pg/mL, respectively. The 1:1 Invisalign® material induced a TNF-α concentration
of 8.54 pg/mL, and the Invisalign® material induced a concentration of 113.10 pg/mL TNF-α.
The LPS induced a concentration of 7.14 pg/mL TNF-α.
At 48 h, the negative and saliva controls had a concentration of 5.58 pg/mL and 3.51
pg/mL of TNF-α, respectively. The 1:1 Invisalign® material and Invisalign® material induced
concentrations of 6.90 pg/mL TNF-α and 66.74 pg/mL TNF-α. For the LPS control, it induced a
concentration of 3.51 pg/mL TNF-α.
5.5.4. IL-6
All concentration values for IL-6 were 11.91 pg/mL, apart from the the 48 h Invisalign®
material that induced 15.57 pg/mL pg/mL.
5.5.5. IL-8
At 24 h, the concentration of IL-8 in the negative and saliva controls was 154.31 pg/mL
and 210.69 pg/mL IL-8, respectively. The 1:1 Invisalign® material induced a concentration of
282.85 pg/mL IL-8, and the Invisalign® material induced a much higher concentration of
10,105.59 pg/mL IL-8. The LPS induced an IL-8 concentration of 148.76 pg/mL.
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At 48 h, the negative and saliva controls had concentrations of 65.67 pg/mL and 30 .61
pg/mL of IL-8, respectively. The 1:1 Invisalign® material induced 244.575 pg/mL IL-8 and the
Invisalign® material induced a very high concentration of 55,037.67 pg/mL IL-8. The LPS control
induced a concentration of 94.22 pg/mL IL-8.
5.5.6. IL-10
The concentration value of IL-10 at 24 h was 3.51 pg/mL for the negative control, 1:1
Invisalign® material sample, and the LPS positive control. The saliva control had a concentration
of 3.63 pg/mL IL-10, and the Invisalign® material induced a concentration of 9.85 pg/mL IL-10.
At 48 h, the negative and saliva control concentrations were 4.15 pg/mL IL-10 and 3.51
pg/mL IL-10, respectively. The concentration of IL-10 in the 1:1 Invisalign® material sample was
5.5 pg/mL, and the Invisalign® material induced 24.90 pg/mL IL-10. The LPS positive control
induced an IL-10 concentration of 7.08 pg/mL.
5.5.7. IL-12p70
The concentration value for IL-12p70 was 3.61 pg/mL for all samples except for 48 h
Invisalign® material sample at 3.91 pg/mL IL-12p70, and the 48 h LPS control that induced 4.05
pg/mL IL-12p70. The minimum detectible concentration of IL-12p70 in the assay is 2.0 pg/mL.
5.6. Statistical Analysis: Mann-Whitney U test
Including all donors and time points from experiments 2-4, the IL-8 concentrations of the
Invisalign® material samples did not significantly differ from the saliva control concentrations of
IL-8 (Mann-Whitney U=89, n1=n2=75, α < 0.05 two-tailed).
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A.

B.

C.

Figure 5.5. Experiment 4
Standard Curves. A.
Concentration (pg/mL) vs.
MFI standard curve for A.
IL-1β. B. IFN-γ and C. TNFα. The standard cocktail was
reconstituted with 250 μL of
Assay Buffer and used as the
top standard, C7. A serial 1:4
dilution was prepared for
standards C6-C1. Assay
buffer was used as the 0
pg/mL standard (C0). All
standards were plated in
duplicate.
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D.

E.

F.

Figure 5.5. (Continued).
Experiment 4 Standard
Curves. Concentration
(pg/mL) vs. MFI standard
curve for D. IL-6. E. IL-8 and
F. IL-10. The standard
cocktail was reconstituted
with 250 μL of Assay Buffer
and used as the top standard,
C7. A serial 1:4 dilution was
prepared for standards C6C1. Assay buffer was used as
the 0 pg/mL standard (C0).
All standards were plated in
duplicate.
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G.

Figure 5.5. (Continued).
Experiment 4 Standard
Curves. Concentration
(pg/mL) vs. MFI standard
curve for G. IL-12p70. The
standard cocktail was
reconstituted with 250 μL of
Assay Buffer and used as the
top standard, C7. A serial 1:4
dilution was prepared for
standards C6-C1. Assay
buffer was used as the 0
pg/mL standard (C0). All
standards were plated in
duplicate.
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Sample

IL-1β

IFN-γ

TNF-α

24 hours
6.95 ± 11.91 ±
1.37
0.00

Negative
control

26.16 ±
12.99

4.71 ±
0.00

Saliva control

23.02 ±
14.07
12.75 ±
1.12

4.71 ±
0.00
4.71 ±
0.00

6.61 ±
3.10
8.54 ±
0.23

Invisalign®

461.83 ±
31.39

4.71 ±
0.00

LPS control

14.65 ±
6.40

4.71 ±
0.00

1:1 Invisalign®

IL-6

IL-8

IL-10

IL12p70

154.31 ±
92.04

3.51 ± 3.61 ±
0.00
0.00

11.91 ±
0.00
11.91 ±
0.00

210.69 ±
133.13
282.85 ±
72.64

3.63 ± 3.61 ±
0.12
0.00
3.51 ± 3.61 ±
0.00
0.00

133.10 ±
18.68

11.91 ±
0.00

10105.59 ±
6720.16

9.85 ± 3.61 ±
0.23
0.00

7.14 ±
0.71

11.91 ±
0.00

148.76 ±
2.30

3.51 ± 3.61 ±
0.00
0.00

48 hours
5.58 ± 11.91 ±
0.00
0.00

65.67 ±
9.84

4.15 ± 3.61 ±
0.64
0.00

Negative
control

3.27 ±
0.83

4.71 ±
0.00

Saliva control

4.08 ±
0.77

4.71 ±
0.00

3.51 ±
0.00

11.91 ±
0.00

30.61 ±
15.42

3.51 ± 3.61 ±
0.00
0.00

1:1 Invisalign®

12.15 ±
3.5

4.71 ±
0.00

6.90 ±7
0.5

11.91 ±
0.00

244.575 ±
71.72

5.55 ± 3.61 ±
0.58
0.00

958.42 ±
49.91

4.71 ±
0.00

66.74 ±
1.80

15.57 ±
0.22

55037.67 ±
45053.01

24.90 ± 3.91 ±
10.58
0.30

5.06 ±
1.62

4.71 ±
0.00

3.51 ±
0.00

11.91 ±
0.00

94.22 ±
4.64

7.08 ± 4.05 ±
1.78
0.44

Invisalign®

LPS control

Table 5.5. Mean Cytokine Expression of THP-1 Cells, Experiment 4. Mean cytokine
expression in pg/mL of THP-1 cells cultured for 24 or 48 hours with different culture
conditions. The negative control has no additive, the saliva control has only artificial saliva
added, the 1:1 Invisalign sample has Invisalign® eluate diluted 1:1 with cell media, the
Invisalign® sample is the addition of Invisalign eluate (no dilution), and the LPS control has
500 ng/ml P. gingivalis LPS. Values shown are the mean of the duplicates reported with
standard error.
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24 hours
500

Conncentration (pg/mL)

450
400
350

Negative control

300

Saliva control

250

1:1 Invisalign

200

Invisalign

150

LPS control

100
50
0

IL-1β

IFN-γ

TNF-α

IL-6

IL-8

IL-10 IL-12p70

48 hours
500

Concentration (pg/mL)

450
400
350

Negative control

300

Saliva control

250

1:1 Invisalign

200

Invisalign

150

LPS control

100
50
0

IL-1β

IFN-γ

TNF-α

IL-6

IL-8

IL-10 IL-12p70

Figure 5.5.1. Mean Cytokine Expression of THP-1 Cells, Experiment 4. Mean
cytokine expression in pg/mL of THP-1 cells cultured for 24 or 48 hours with
different culture conditions. The negative control has no additive, the saliva control
has only artificial saliva added, the 1:1 Invisalign sample has Invisalign® diluted 1:1
with cell media, the Invisalign® sample is the addition of Invisalign (no dilution), and
the LPS control has 500 ng/ml P. gingivalis LPS. Values shown are the mean of the
duplicates with standard error.
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CHAPTER 6: DISCUSSION
6.1. Particle Size
The dynamic light scattering (DLS) results indicate that the radius of the Invisalign®
material particles was, on average, between 502.9 and 873.5 nm. The smallest particles had a
mean radius of 0.71 nm, and the largest detected had a mean radius of 552.6 nm. The Invisalign®
material preparation steps were taken from Premaraj et al. (2014), but their values for the ground
eluate were much larger when measured with a measure scope. They found particles ranging from
86 x 56 μm to 186 x 161 μm in size. The size difference could be largely attributed to the method
used to determine the size. DLS is a technique well-studied in characterizing nanoparticles
(Domingos et al. 2009; Souza et al. 2016).
The smallest particles are of most interest because they classify as nanoparticles. A
nanoparticle is a particle with a diameter between 1 to 100 nanometers (Lewinski et al. 2008).
Nanoparticles can interact with the immune system and become immunotoxic, increasing the
expression of pro-inflammatory cytokines (Elsabahy and Wooley 2013). Although it was the
supernatant of the Invisalign® material/artificial saliva soakings that was collected for the eluate,
there may be nanoparticles remaining in the eluate that could be contributing to the immune
reaction. When worn in the mouth, Invisalign® material may be abraded by bruxing of the teeth,
which may release nanoparticles, although the size of particles that may be created by bruxing is
not known. In addition, routine brushing and cleaning of Invisalign trays at least twice daily could
also possibly abrade the plastic and release nanoparticles.
6.2. Experiment 1
The first experiment yielded interesting results for the expression of TNF-α, IL-6, and IL8. TNF-α concentrations were low in saliva and negative controls at 24 and 72 h. Invisalign®
material samples induced approximately 5x higher TNF-α concentrations than the negative
controls, and the LPS control induced >1000 pg/mL of TNF-a. These results suggest that
Invisalign® material stimulates TNF-α expression from PBMCs. TNF-α is a pro-inflammatory
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cytokine produced by lymphocytes, monocytes, and NK cells (Borish and Steinke 2003;
Dinarello 2000), which are included in the pooled PBMCs. The TNF-α concentrations at 72 hours
were lower than at 24 hours, most likely due to increased cell death with increased culture time.
Invisalign® material eluate was shown to have a cytotoxic effect on oral keratinocytes (Premaraj
et al. 2014), and TNF-α can also have a direct cytotoxic effect on cells (Borish and Steinke 2003;
Dinarello 2000).
Unexpectedly, IL-6 and IL-8 production from PBMC were high without any stimulants,
reaching over 49,000 pg/mL for IL-6 and over 16,000 pg/mL for IL-8. Because all values for IL-6
and IL-8 exceeded the highest standard concentration (around 10,000 pg/mL) the values of the
different samples cannot be accurately compared. To do this, the samples would need to be
diluted to within the range of the assay. The question is why there was such high cytokine
expression in negative controls. Bacterial contamination during culture conditions could lead to
increased cytokine expression in negative controls, but there would have likely been signs of this
with the TNF-α values. Similarly, another possible cause of the high values was that the FBS
used in the cell media was not heat-inactivated. Heat-inactivation of complement in FBS is
required, which can activate immune cells unwantedly (Heat Inactivation 1996; Gibco fetal
bovine serum (FBS) 2014). For the next experiment, FBS was heat-inactivated.
Another possibility for the high IL-8 and IL-6 concentrations was a mixed lymphocyte
reaction (MLR). This occurs when the T-cells recognize MHC molecules that are not compatible,
causing the T-cells to divide, proliferate, and secrete cytokine, similar to a Graft Versus Host
Disease reaction (Janeway et al. 2001). The company from which the cells were purchased claims
to test the cells for reactivity, though (Human mononuclear cells 2020), which would mitigate the
risk for a MLR. For the next experiment, cells from three individual donors were used to rule out
any reactivity between cells.
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6.3. Experiment 2
Induction of TNF-α and IL-6 were less than 1 pg/mL for all samples besides the LPS
controls, which were still under 10 pg/mL (compared to the first experiment where LPS controls
were >1,000 pg/mL for TNF-α). Neither Invisalign® material nor LPS induced expression of
TNF-α or IL-6 for any donor. Production of IL-8 was slightly increased in response to Invisalign
and more variable than the other two cytokines. In Donor 1, the IL-8 concentration for the
Invisalign® material sample was increased from the negative and saliva controls, and the LPS
positive control was higher than the Invisalign® material sample. In Donor 1, Invisalign® material
may have induced an increase in IL-8 production, although the values are still very low for all
samples. Donors 2 and 3 showed slightly increased LPS controls, but the Invisalign® material did
not cause increased expression of IL-8. Donor 1 was the only smoker from the three donors and
had the highest concentration values for IL-8.
6.4. Experiment 3
To obtain a higher positive control for the next experiment, LPS was vortexed for 15
minutes before use as it is a lipid and needs even distribution. A higher concentration of LPS was
also added (1 ug/mL) to obtain increased cytokine expression, though both the 500 ng/mL and 1
μg/mL LPS samples were both >10,000 pg/mL for IL-8, indicating that the LPS addition in
experiment 2 (500ng/mL) was not the cause for the low positive control values. The standard
curve for experiment 3 showed error between duplicates, especially at the C4 standard point. This
was most likely due to an issue with the serial dilution at the C4 standard and/or pipetting error.
The general trend for this experiment showed increased IL-8 values in Donors 1 and 3 for
all samples and controls compared to IL-6 and IL-8 concentrations. In Donor 1, the TNF-α
concentration in response to Invisalign® material was slightly higher than the saliva control. For
IL-6, Invisalign® induced from Donors 1 and 3 almost 4x the negative control concentration.
However, the values were still under 400 pg/mL, much less than the positive controls (≥10,000
pg/mL) and the Invisalign® samples for IL-8 in Donors 1 and 3 (>6,000/mL). Donor 2 had low
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concentrations for all samples; the LPS control for IL-8 was only 71.16 pg/mL. There is no
obvious explanation for the difference in expression in the different donors. Every donor will
react differently to stimuli. In Experiment 2, the donor who smoked had the highest
concentrations values of IL-8. In this experiment, of the donors with the highest concentration
values of IL-8, one was a smoker (Donor 1) and the other was not (Donor 3).
6.5. Experiment 4
Because there was a stark difference in reactivity between donors in the previous
experiments, the switch was made to THP-1 cells for this experiment. Using the same cell line in
repeated experiments will make the results more predictable and easier to validate. THP-1 cells
are monocytic and therefore represent the monocytes of PBMC.
The standard curves for experiment 4 showed some pipetting error between duplicates
and the lower values of the standard curves were slightly lower than expected, possibly due to
flow cytometer settings. For the next experiment, the voltages and events collected will be
increased, as both the MFIs and number of events were lower than recommended for this
experiment.
The cytokine showing the most variation in samples, and the highest expression was IL8. LPS did not induce much IL-8 expression, but the Invisalign® material greatly stimulated
expression of IL-8 with values over 10,000 pg/mL at both 24 and 48 hours. The 1:1 diluted
Invisalign® material also induced expression of IL-8 but less so than the concentrated eluate. IL-8
is a pro-inflammatory chemokine that directs neutrophils to the site of inflammation (Borish and
Steinke 2003; Dinarello 2000). One of the adverse reactions reported from Invisalign® material is
swelling of gingival tissues, and neutrophils play a key role in edema. Neutrophils promote
inflammation by interacting with the vascular endothelia during extravasation from the blood
vessels and by secreting compounds that increase the permeability of the vasculature, such as
arachidonic acid (Scott and Krauss 2012).
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Invisalign® material also induced expression of IL-1β, but in much lower concentrations
than IL-8. TNF-α was also slightly increased from the negative controls, but still less than 100
pg/mL. IL-1β and TNF-α are both pro-inflammatory cytokines, with IL-1β playing a role in acute
inflammation/fever and also chronic inflammation (Cameron and Kelvin 2000-2013). The
mechanism of TNF is similar to IL-1, and the effects are synergistic (Borish and Steinke 2003;
Dinarello 2000).
The positive control values for IL-8, IL-1β, and TNF-α were all low. To obtain higher
reactivity to LPS in future experiments, the monocytes should be differentiated to macrophages
by phorbol myristate acetate (PMA). In one study, LPS induced TNF-α concentrations 2.5 higher
in differentiated THP-1 cells than in undifferentiated cells (Takashiba et al. 1999). When
differentiated to macrophages, THP-1 cells expressed high levels of CD14, a macrophagespecific differentiation antigen (Takashiba et al. 1999). CD14 facilitates the LPS activation of
cells by transferring the LPS to the Toll-like receptor complex (Plevin et al. 2016).
The use of P. gingivalis LPS instead of E. coli LPS also may have had an effect on the
positive control results. The two different types of LPS activate monocytes in different ways; P.
gingialis LPS is atypical in that it utilizes mainly TLR2, whereas E. coli LPS utilizes TLR4
(Zhang et al. 2008). One study found that P. gingivalis LPS induced expression of IL-1β, TNF-α,
and IL-6 in THP-1 cells and slightly more so than E. coli LPS at some timepoints (Zhang et al.
2008). Another study found that E. coli LPS induced the expression of IL-1β and IL-8 in THP-1
cells, more so than P. gingivalis LPS (Yiemwattana et al. 2017). Each of these studies used
1μg/mL of P. gingivalis LPS instead of the 500ng/mL used in this experiment. Although different
strains and extraction methods of LPS can cause different activity levels (Zhang et al. 2017), it is
expected that P. gingivalis LPS would induce expression of IL-6, IL-8, TNF-α, and IL- β, with
proper PMA differentiation. In future experiments, different concentrations of P. gingivalis LPS
may be used, or the experiment may be conducted with E. coli LPS.
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The values for IFN-γ, IL-6, IL-10, and IL-12p70 were all very low. The positive LPS
controls also showed low values for these cytokines. It was not expected that IFN-γ would be
highly expressed as it is produced mainly by natural killer cells and T-cells. Macrophages can
also produce IFN-γ, but less commonly (Dinarello 2000; Varma et al. 2002).
IL-10 is an anti-inflammatory cytokine produced by monocytes, macrophages, and Tcells (Couper et al. 2008). In THP-1 cells differentiated to macrophages by phorbol myristate
acetate (PMA), one study found there was no significant increase in IL-10 when stimulated with
LPS (Liu et al. 2018). Pengal et al. (2006) found that macrophages stimulated with LPS had
higher concentrations of IL-10 only when also activated with IgG immune complexes, not LPS
alone. These studies show that IL-10 may not be expressed solely by macrophages stimulated
with LPS.
IL-12p70 is produced by monocytes, macrophages, B cells, polymorphonuclear
neutrophils, and mast cells. In one study, IL-12p70 was stimulated in THP-1 cells by 1μg/mL
LPS after PMA differentiation to macrophages (Utsugi et al. 2003). In future experiments, the
THP-1 cells should be differentiated to macrophages.

6.6. Limitations of the Study
Many limitations of the experiments were described within the discussion. Each
experiment came with its own unique challenges and troubleshooting that needed to be overcome
before future experiments.
6.6.1. Reproducibility
To verify the reproducibility of a study and draw statistical conclusions, the experiment
needs to be repeated multiple times. One of the main limitations of this study is that each run of
the experiment was repeated once, and then the changes needed to be made. Thus, limited
conclusions can be drawn. One of the challenges of performing a novel study is the methodology,
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and there were multiple attempts to succeed in that regard. Troubleshooting, time, and finances
were all limiting factors in repeating the assay.
6.6.2. In vitro Research
Another limitation of this study is studying cells under in vitro conditions. Although
THP-1 cells are commonly used to study a variety of immune responses, the results cannot be
fully extrapolated to in vivo conditions. THP-1 cells were chosen to standardize cells and for ease
of repeatability of the study, but the results cannot be fully extrapolated to in vivo conditions as
the response of the immortalized cells may be different from primary monocytes in humans
(Bosshart and Heinzelmann 2016). The PBMCs from different donors showed highly variable
results after stimulation and makes for difficult reproducibility.
The culture conditions used in this study also cannot be extrapolated to what would
happen in vivo when a patient is wearing Invisalign® aligners. This study's results serve as a
jumping-off point for future research that will more closely relate to the patients using this
product.
6.7. Conclusions
The results of this are that Invisalign® material stimulates IL-8 expression in certain
individual donor PBMCs and THP-1 monocytes, though not significantly (Mann-Whitney
U=89, n1=n2=75, α < 0.05 two-tailed). Invisalign® material might also stimulate slight expression
of TNF-α in pooled PBMCs, certain individual donor PBMCs, and THP-1 cells. IL-6 was slightly
increased in certain individual donor PBMCs. IL-1β was also slightly stimulated by Invisalign®
material in THP-1 cells. IL-10, IL-12p70, IFN-γ, and IL-6 were not detected after THP-1
monocytes were stimulated with Invisalign® material.
6.8. Future Research
Further research will include reproducing the results in multiple other rounds of the cell
culture and assay. Also, adding eluate that has been soaked for different time points will
determine whether increased or decreased soaking time of the Invisalign® material produces
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different cytokine expression. Other research could include different culture times for the cells to
determine whether cytokine production is varied at different points in the cell culture. Another
prudent addition to future studies would be adding isocyanate to the samples being studied to
determine if the cytokine expression after Invisalign® material addition is similar to that induced
by isocyanate. There was a potential trend of PBMCs from smokers reacting more to stimuli than
nonsmokers, which could be investigated in future studies, also.
The nanoparticles found in the Invisalign® particulate material is another avenue that
could be pursued in further research. To determine if there are any nanoparticles in the eluate, the
Invisalign® eluate should be evaluated with DLS.
Other research could look at the effect of this Invisalign® material on other immune cells,
such as mast cells. This would give more information on the allergic potential of the material by
studying the degranulation of mast cells.
The primary goal of this in vitro research was to provide evidence to translate the
findings to the patients who are being treated with Invisalign® aligners. One future project will
include collecting blood samples from patients who have used Invisalign® aligners and studying
the cytokine profile in response to Invisalign. To take it a step further, comparing samples from
patients who had adverse reactions from the product from those who did not. This research would
begin to elucidate why certain patients have reactions and if there is any way to screen for or
prevent those reactions.
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